Tessera Therapeutics
Edit info- Founded: 2020
- Location: Cambridge, MA
- Employee range: 50 - 200
- Funding: $300M C Apr 2022; $230M B Jan 2021
tesseratherapeutics.com linkedin.com job board
Business:
Gene Writing
About:
Tessera Therapeutics is pioneering a new category of genome engineering technology called Gene Writing to cure disease by writing in the code of life. Gene Writing is a versatile technology platform that can permanently make small and large alterations to the human genome. The technology can be used to target single point mutations, insertions and deletions or write entire genes. To apply their technology, Tessera is using tissue-targeting non-viral delivery technology to make genetic alterations where they are needed. With their technology, Tessera is aiming to address major unmet medical needs with potentially curative and accessible therapies.
Jobs:
News:
We are grateful for the opportunity to give back to our community. #TeamTessera recently came together for our second annual Day of Service, volunteering with local nonprofits in the #Boston area.
A
linkedin
Nov 28, 2024
New hires
external-link
Tessera Therapeutics Presents New Preclinical Data Highlighting Advancements Across Its Portfolio Programs and Platforms at the American Society of Gene and Cell Therapy 27th Annual Meeting - Yahoo Fi
googlenews
May 10, 2024
Science/business updates
external-link
The twelve hottest biotech companies in the Boston area - Labiotech.eu
googlenews
Mar 12, 2024
Science/business updates
external-link
Tessera Therapeutics to Present New Data Across Preclinical - GlobeNewswire
googlenews
Apr 22, 2024
Science/business updates
external-link
Tessera makes the case for gene writing tech at JPM
fiercebiotech.com
Dec 19, 2024
Science/business updates
external-link
ASGCT 2023: New preclinical updates from Tessera, Tune ...
fiercebiotech.com
Dec 19, 2024
Science/business updates
external-link
Tessera Therapeutics stacks up more than $300M in series C funds to bolster new gene-editing platforms - Fierce Biotech
googlenews
Apr 19, 2022
Funding-related
external-link
Bluebird exec spreads wings, heads over to Tessera for 'irresistible opportunity'
web
Dec 19, 2024
New hires
external-link
Early Reporting of 2025 Prescription Drug Price Changes
crunchbase
Dec 20, 2024
Science/business updates
external-link
Serotiny and Tessera Therapeutics enter into collaboration to engineer and optimize programmable Gene Writer proteins
crunchbase
Feb 28, 2022
Science/business updates
external-link
Breakout Ventures Welcomes Five New Venture Partners - Business Wire
googlenews
Mar 26, 2024
New hires
external-link
Tessera Therapeutics Receives Investment From Bill & Melinda Gates Foundation - FinSMEs
googlenews
Dec 18, 2024
Funding-related
external-link
Tessera Therapeutics Announces R&D Collaboration with Cystic Fibrosis Foundation as Part of a Portfolio of Complementary Technologies Advanced by Flagship’s Pioneering Medicines to Treat Cystic Fibros
googlenews
Nov 3, 2021
Science/business updates
external-link
Tessera Therapeutics Expands Leadership and Board - Business Wire
googlenews
Aug 24, 2022
New hires
external-link
Michael Severino trades in AbbVie perch for CEO role at Flagship’s gene medicines biotech Tessera
web
Dec 19, 2024
New hires
external-link
Tessera’s gene editing offers hope for sickle cell patients - Drug Target Review
googlenews
Dec 18, 2024
Science/business updates
external-link
Turbulence in Pharma: A Wave of Layoffs Sweeps Through the Industry - BSA bureau
googlenews
May 8, 2024
New hires
external-link
JPM23: With preclinical gene writing data on display, Tessera CEO's spirits not dampened by California's wild weather
web
Dec 19, 2024
Science/business updates
external-link
Tessera Therapeutics Receives Investment from The Bill and Melinda Gates Foundation
crunchbase
Dec 18, 2024
Funding-related
external-link
Fierce Biotech Layoff Tracker 2024: Redundancies at Ring; Editas cuts 65% of staff - Fierce Biotech
googlenews
Jan 4, 2024
New hires
external-link
Feud between Prime and Tessera, two gene-editing companies, spills out into public - STAT
googlenews
Oct 28, 2024
Science/business updates
external-link
Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform - Business Wire
googlenews
Apr 19, 2022
Funding-related
external-link
Prime Medicine Spat with Tessera Rumbles on at ESGCT - Genetic Engineering & Biotechnology News
googlenews
Oct 25, 2024
Science/business updates
external-link
Can “Gene Writing” Deliver What Gene Editing Can’t?
web
Dec 20, 2024
Science/business updates
external-link
A key decision on compounding is expected this week - STAT
googlenews
Dec 18, 2024
Science/business updates
external-link
Today we announced preclinical data presented at the 66th American Society of Hematology Annual Meeting, highlighting advances in our in vivo therapies for sickle cell disease (SCD) and T cell therapi
linkedin
Dec 12, 2024
Science/business updates
external-link
Quotient Therapeutics Appoints Sir Mene Pangalos, Ph.D. to Board of Directors - The Manila Times
googlenews
Nov 7, 2024
New hires
external-link
Tessera Therapeutics Names Cynthia M. Patton as General Counsel and Secretary
web
Dec 19, 2024
New hires
external-link
Leading Gene Writing Company Tessera Therapeutics Announces Pivotal Expansion of Leadership Team - Business Wire
googlenews
Jul 14, 2021
New hires
external-link
Former bluebird CMO David Davidson Lands Exec Role at Tessera Therapeutics
crunchbase
Apr 7, 2021
New hires
external-link
We are excited that our team will be presenting at this year's Society for Immunotherapy of Cancer (SITC) Annual Meeting.
If you are attending, please stop by our poster presentation to catch up on
linkedin
Nov 19, 2024
Science/business updates
external-link
Programmable genetics gets more cash as Tessera Therapeutics gets a $230 million infusion
crunchbase
Jan 12, 2021
Funding-related
external-link
Tessera gets sickle cell funding; Corvus shares slide on eczema data - BioPharma Dive
googlenews
Dec 18, 2024
Funding-related
external-link
Tessera Therapeutics Presents New Preclinical Data Highlighting Advancements Across Its Portfolio Programs and ...
crunchbase
May 26, 2024
Science/business updates
external-link
Tessera Therapeutics to Present New Data Across Preclinical Programs for its Gene Writing™ and Delivery Platforms at the American Society of Gene and Cell Therapy 27th Annual Meeting
web
Dec 20, 2024
Science/business updates
external-link
Tessera Therapeutics taps former BeiGene CFO Howard Liang to join race to CRISPR 3.0 - Endpoints News
googlenews
Jul 14, 2021
New hires
external-link
Tessera Therapeutics Highlights Advancements Across its Gene Writing™ and Delivery Platforms Including Proof of Concept Data in Non-Human Primates
web
Dec 20, 2024
Science/business updates
external-link
Biomanufacturing Parallels the Semiconductor Chip Revolution
web
Dec 19, 2024
Science/business updates
external-link
Tessera Therapeutics to Present New Preclinical Data From In Vivo Programs for Sickle Cell Disease and T-Cell Therapies at the 66th American Society of Hematology Annual Meeting
web
Dec 19, 2024
Science/business updates
external-link
Can “Gene Writing” Deliver What Gene Editing Can’t? - The Scientist
googlenews
Dec 12, 2022
Science/business updates
external-link
After obesity, Pfizer and Flagship pick 2 more targets for multibillion-dollar partnership - Fierce Biotech
googlenews
Aug 28, 2024
Science/business updates
external-link
The biotech news you need to read today - STAT
googlenews
Oct 28, 2024
Science/business updates
external-link
Bluebird's chief medical officer flies the nest to gene writing biotech Tessera
crunchbase
Apr 7, 2021
New hires
external-link
The Week’s 10 Biggest Funding Rounds: More Musk As The Boring Company Digs Up $675M, Upside Foods Cultivates $400M Round
crunchbase
Apr 22, 2022
Funding-related
external-link
Why AbbVie’s former president has high hopes for this Flagship-backed biotech - PharmaVoice
googlenews
Aug 7, 2023
Science/business updates
external-link
Biotechnology Company Tessera Therapeutics Raises Over $300 Million
crunchbase
Apr 28, 2022
Funding-related
external-link
IPO Watchlist: The biopharma unicorns that could go public in 2024 - PitchBook News & Analysis
googlenews
Mar 27, 2024
Funding-related
external-link
Top Five Privately Held Gene Editing Therapy Companies - Genetic Engineering & Biotechnology News
googlenews
May 31, 2024
Science/business updates
external-link
Tessera Therapeutics Receives Investment to Develop Curative In Vivo Genetic Treatment for Sickle Cell Disease - GlobeNewswire
googlenews
Dec 18, 2024
Funding-related
external-link
Tessera Therapeutics Awarded the Prix Galien USA 2023 for Best Startup
web
Dec 19, 2024
Science/business updates
external-link
The European Society of Gene and Cell Therapy Annual Meeting begins tomorrow. We look forward to showcasing the continued advances of our #GeneWriting and lipid nanoparticle (LNP)-based delivery platf
linkedin
Nov 19, 2024
Science/business updates
external-link
Serotiny and Tessera Therapeutics enter into collaboration to engineer and optimize programmable Gene Writer proteins - Business Wire
googlenews
Feb 28, 2022
Science/business updates
external-link
Nucleotide Novellas: Tessera Therapeutics Writes Genetic Medicines to Cure Diseases - Genetic Engineering & Biotechnology News
googlenews
Dec 12, 2022
Science/business updates
external-link
Tessera Therapeutics Corrals More Than $230 Million for New Genetic Medicines - The Wall Street Journal
googlenews
Jan 12, 2021
Funding-related
external-link
Tessera Therapeutics Presents New Preclinical Data Highlighting Advancements Across Its Portfolio Programs and Platforms at the American Society of Gene and Cell Therapy 27th Annual Meeting
web
Dec 19, 2024
Science/business updates
external-link
Behind the Breakthroughs: Towards In Vivo Genome Editing Humans - Inside Precision Medicine
googlenews
Nov 21, 2024
Science/business updates
external-link
Leading Gene Writing Company Tessera Therapeutics Announces Pivotal Expansion of Leadership Team
crunchbase
Jul 14, 2021
New hires
external-link
Tessera Therapeutics Presents New Data Demonstrating the Potential of Gene Writing™ Technology at the American Society of Gene and Cell Therapy 26th Annual Meeting
web
Dec 20, 2024
Science/business updates
external-link
Tessera bags $50 million investment from Gates Foundation - The Pharma Letter
googlenews
Dec 18, 2024
Funding-related
external-link
Former bluebird CMO David Davidson Lands Exec Role at Tessera Therapeutics - BioSpace
googlenews
Apr 7, 2021
New hires
external-link
We're honored to be named a BioSpace 2025 Best Places to Work in Biopharma! #TeamTessera’s dedication and passion fuel our mission to cure disease by writing in the code of life. Join us in making a d
linkedin
Nov 19, 2024
New hires
external-link
Tessera Therapeutics, Inc. - Massachusetts Biotechnology Council
googlenews
Jul 28, 2021
New hires
external-link
BioSpace Announces 2025 Best Places to Work in Biopharma - BioSpace
googlenews
Nov 12, 2024
Science/business updates
external-link
Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform
crunchbase
Apr 19, 2022
Funding-related
external-link
Bluebird’s regulatory chief departs two days after historic gene therapy nod to join Flagship’s Tessera
web
Dec 19, 2024
New hires
external-link
Tessera Therapeutics Receives Investment to Develop Curative In Vivo Genetic Treatment for Sickle Cell Disease
crunchbase
Dec 18, 2024
Funding-related
external-link
Tessera Therapeutics Highlights Advances Across In Vivo Programs for Sickle Cell Disease and T-Cell Therapies at the 66th American Society of Hematology Annual Meeting
crunchbase
Dec 9, 2024
Science/business updates
external-link
Tessera Therapeutics to Present New Preclinical Data From - GlobeNewswire
googlenews
Nov 5, 2024
Science/business updates
external-link
Flagship launches first UK biotech Quotient with genome sequencing platform - Fierce Biotech
googlenews
Nov 21, 2023
Science/business updates
external-link
JPM23: With preclinical gene writing data on display, Tessera CEO's spirits not dampened by California's wild weather - Fierce Biotech
googlenews
Jan 17, 2023
Science/business updates
external-link
From Big Pharma to little Tessera, Michael Severino rewrites his next chapter as CEO of Flagship biotech - Fierce Biotech
googlenews
Jun 2, 2022
New hires
external-link
Tessera Cuts Dozens of Jobs Following Positive Preclinical Results
crunchbase
Apr 26, 2024
New hires
external-link
Flagship’s gene editing startup Tessera cuts jobs as it shifts resources to clinic - Endpoints News
googlenews
Apr 23, 2024
Science/business updates
external-link
Tessera Rewrites the Genome Script Using Mobile Genetic Elements
crunchbase
Mar 10, 2021
Science/business updates
external-link
Tessera Therapeutics Highlights Advances Across In Vivo Programs for Sickle Cell Disease and T-Cell Therapies at the 66th American Society of Hematology Annual Meeting - GlobeNewswire
googlenews
Dec 9, 2024
Science/business updates
external-link
Tessera Therapeutics to Present New Data Showcasing the - GlobeNewswire
googlenews
May 2, 2023
Science/business updates
external-link
Behind the Breakthroughs: Towards In Vivo Genome Editing Humans
linkedin
Dec 19, 2024
Science/business updates
external-link
Tessera Therapeutics Presents New Preclinical Data in In Vivo AATD and SCD Programs at the 31st Annual Congress of the European Society of Gene and Cell Therapy
web
Dec 19, 2024
Science/business updates
external-link
Tessera Therapeutics Presents New Preclinical Data Highlighting Advancements Across Its Portfolio Programs and Platforms at the American Society of Gene and Cell Therapy 27th Annual Meeting
crunchbase
May 10, 2024
Science/business updates
external-link
Tessera Therapeutics to Present New Data Showcasing the Broad Potential of its Gene Writing™ and Delivery Platforms at the American Society of Gene and Cell Therapy 26th Annual Meeting
web
Dec 20, 2024
Science/business updates
external-link
In vivo editing data advances lift hopes for better access - BioCentury
googlenews
Oct 28, 2024
Science/business updates
external-link
Tessera Therapeutics taps former BeiGene CFO Howard Liang to join race to CRISPR 3.0
crunchbase
Jul 14, 2021
New hires
external-link
#ICYMI, we are looking forward to attending the American Society of Hematology Annual Meeting to showcase our latest progress towards in vivo therapies for sickle cell disease and T-cell therapies.
L
linkedin
Nov 19, 2024
Science/business updates
external-link
Tessera Therapeutics to Present New Preclinical Data From In Vivo Programs for Sickle Cell Disease and T-Cell Therapies at the 66th American Society of Hematology Annual Meeting
crunchbase
Nov 5, 2024
Science/business updates
external-link
Flagship Pioneering is All Hands on Deck for Cystic Fibrosis - BioSpace
googlenews
Nov 3, 2021
Science/business updates
external-link
Despite industry-wide stock slump, Mass. biotech startups raised $5.1 billion in the first half of 2022
web
Dec 19, 2024
Funding-related
external-link
Tessera Therapeutics scores $230M to ramp up 'gene ...
fiercebiotech.com
Dec 19, 2024
Funding-related
external-link
Tessera Therapeutics Receives Investment to Develop Curative In Vivo Genetic Treatment for Sickle Cell Disease
web
Dec 19, 2024
Funding-related
external-link
Today, we announced we have entered into an agreement with the Bill & Melinda Gates Foundation to jointly fund our in vivo program for sickle cell disease (SCD). Read more here: https://lnkd.in/e-4JuF
linkedin
Dec 18, 2024
Funding-related
external-link
Intellia, ReCode partner on genetic medicines for cystic fibrosis - BioPharma Dive
googlenews
Feb 15, 2024
Science/business updates
external-link
BRIEF—bluebird bio exec flies nest to join Tessera Therapeutics
web
Dec 19, 2024
New hires
external-link
Nucleotide Novellas: Tessera Therapeutics Writes Genetic Medicines to Cure Diseases
web
Dec 19, 2024
Science/business updates
external-link
Tessera Therapeutics Presents Non-Human Primate (NHP) Data in Alpha-1 Antitrypsin Deficiency (AATD) Program at the Federation of American Societies for Experimental Biology Meeting on Genome Engi
web
Dec 19, 2024
Science/business updates
external-link
📅 Join us at ASH 2024, where our team will be showcasing our preclinical data for our in vivo programs in sickle cell disease and T cell therapies. If you're attending, be sure to stop by our oral an
linkedin
Dec 12, 2024
Science/business updates
external-link
What Makes a Company a Great Place to Work? Moderna and Tessera Share Their Insights
web
Dec 19, 2024
Science/business updates
external-link
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com